Skip to main content
. 2002 Apr 19;6(3):251–259. doi: 10.1186/cc1498

Table 2.

Characteristics of patients

Variable Steroid therapy group Standard therapy group Total χ 2 P
All patients 20 (50%) 20 (50%) 40 0.417 0.748
 Female 7 (43.8%) 9 (56.3%) 16
 Male 13 (54.2%) 11 (45.8%) 24
Mean age (years) (mean ± SD) 57.8 ± 17.7 56.5 ± 16.4 57.1 ± 16.9 0.818
Underlying diseases 11 (40.7%) 16 (59.3%) 27 2.849 0.176
 Rapidly fatal - - -
 Ultimately fatal 2 (50%) 2 (50%) 4
 Nonfatal 9 (39.1%) 14 (60.9%) 23
No underlying diseases 9 (69.2%) 4 (30.8%) 13
APACHE II (mean ± SD) 15.4 ± 5.5 17.9 ± 8.0 16.6 ± 6.9 0.249
Maximum SOFA (mean ± SD) 7.8 ± 3.9 9.3 ± 4.0 8.5 ± 4.0 0.257
Acquisition of infection 0.143 1.000
 Community 16 (51.6%) 15 (48.4%) 31
 Hospital 4 (44.4%) 5 (55.6%) 9
Sepsis categories 0.456 0.531
 Sepsis 8 (57.1%) 6 (42.9%) 14
 Severe sepsis 8 (47.1%) 9 (52.9%) 17
 Septic shock 4 (44.4%) 5 (55.6%) 9
Positive cultures 2.345 >0.05
 Gram-negative infection 4 (36.4%) 7 (63.6%) 11
 Gram-positive infection 10 (66.7%) 5 (33.3%) 15
Candida infection 1 (33.3%) 2 (66.7%) 3
 Polymicrobial infection 3 (60.0%) 2 (40.0%) 5
Negative cultures 6 (46.2%) 7 (53.8%) 13
Organ failure 16 (47.1%) 18 (52.9%) 34
DIC 5 (45.5%) 6 (54.5%) 11
Laboratory measurements (mean ± SD)
 Leukocytes (/mm3) 16,057 ± 12,568 14,781 ± 7,317 0.697
 Platelets (/mm3) 183,050 ± 137,983 192,800 ± 127,157 0.324
 ESR (mm/h) 69 ± 36 49 ± 33 0.081
 CRP (mg/l) 67 ± 16 67 ± 24 0.981
 Fibrinogen (mg/dl) 814 ± 394 434 ± 198 0.002
Median stay in hospital (days) 14 (95% CI 11.09–20.08) 13 (95% CI 10.13–16.37) 0.406
Median time to death (days) 5 (95% CI, 2.55–8.20) 5.5 (95% CI, 2.19–13) 0.496
Non-survivors 8 (40%) 12 (60%) 20 1.600* 0.343
Survivors 12 (60%) 8 (40%) 20

*Fisher's χ2 test. CI, confidence interval; DIC, disseminated intravascular coagulation; ESR, erythrocytes sedimentation rate.